Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes

Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai [1][4] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (177Lu) and Lead-203 (203Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with 177Lu can predict behavior with the therapeutic isotope Actinium-225 (225Ac) and similarly for 203Pb with 212Pb [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner, which can be tailored to patient needs without restarting the drug development process [3] Group 3: Clinical Trials and Partnerships - The MP0712 candidate, which targets DLL3 and is co-developed with Orano Med, is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, focusing on 225Ac as a therapeutic payload and 177Lu as an imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes precisely to tumor lesions, addressing limitations of traditional radioligand therapy, such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while minimizing harm to healthy tissues, leveraging the unique properties of DARPins [9] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for challenging medical conditions, with proprietary programs in various stages of development and partnerships with leading pharmaceutical companies [10]